Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604914616> ?p ?o ?g. }
- W2604914616 endingPage "556" @default.
- W2604914616 startingPage "550" @default.
- W2604914616 abstract "Background: Shortcomings of interscalene brachial plexus blockade include technical failure and rebound pain. Bupivacaine liposome injectable suspension, a sustained release preparation, is used for surgical-site administration. The purpose of this study was to evaluate these 2 postoperative pain management strategies in patients undergoing shoulder arthroplasty. Methods: In a non-blinded, randomized controlled trial of participants undergoing primary shoulder arthroplasty, patients were randomized to interscalene brachial plexus blockade or intraoperative soft-tissue infiltration of bupivacaine liposome injectable suspension. The primary outcome variable was morphine equivalent units consumed over the first 24 hours postoperatively. Secondary outcomes included morphine equivalent units consumed intraoperatively and a visual analog scale (VAS) for pain at 0, 8, 16, and 24 hours. Results: Seventy-eight patients were randomized to interscalene brachial plexus blockade treatment (the blockade group) and 78 patients were randomized to bupivacaine liposome injectable suspension treatment (the suspension group). The mean total postoperative narcotic consumption (and standard deviation) over 24 hours after the surgical procedure was 14.8 ± 11.3 morphine equivalent units in the blockade group compared with 14.4 ± 16.8 morphine equivalent units in the suspension group (p = 0.849). Intraoperative narcotics were significantly lower (p < 0.001) in the blockade group (8.9 ± 4.1 morphine equivalent units) compared with the suspension group (16.2 ± 7.0 morphine equivalent units). The mean VAS pain score was significantly lower in the blockade group than in the suspension group at 0 hours postoperatively (0.8 ± 2.2 compared with 3.3 ± 2.7 points; p < 0.001) and at 8 hours postoperatively (1.4 ± 2.4 compared with 3.2 ± 2.2 points; p < 0.001), but it was not significantly different at 16 hours postoperatively (4.3 ± 2.8 compared with 3.8 ± 2.4 points; p = 0.348). The VAS pain scores were significantly higher (p = 0.021) in the blockade group (4.9 ± 2.7 points) compared with the suspension group (3.9 ± 2.3 points) at 24 hours postoperatively. Conclusions: Patients treated with bupivacaine liposome injectable suspension required an equivalent amount of postoperative narcotics and greater intraoperative narcotics compared with patients treated with interscalene brachial plexus blockade. Although interscalene brachial plexus blockade provided improved pain scores for the first 8 hours after the surgical procedure, pain scores were worse at 24 hours. The optimal postoperative pain regimen for shoulder arthroplasty and the cost-effectiveness of analgesic techniques require further investigation. Level of Evidence: Therapeutic Level II . See Instructions for Authors for a complete description of levels of evidence." @default.
- W2604914616 created "2017-04-14" @default.
- W2604914616 creator A5006226053 @default.
- W2604914616 creator A5007247253 @default.
- W2604914616 creator A5033038090 @default.
- W2604914616 creator A5045525636 @default.
- W2604914616 creator A5075639504 @default.
- W2604914616 creator A5085565942 @default.
- W2604914616 date "2017-04-05" @default.
- W2604914616 modified "2023-10-18" @default.
- W2604914616 title "Randomized Controlled Trial of Interscalene Block Compared with Injectable Liposomal Bupivacaine in Shoulder Arthroplasty" @default.
- W2604914616 cites W1809242180 @default.
- W2604914616 cites W1840457638 @default.
- W2604914616 cites W1896208131 @default.
- W2604914616 cites W1917945624 @default.
- W2604914616 cites W1988728097 @default.
- W2604914616 cites W1989547015 @default.
- W2604914616 cites W1990437631 @default.
- W2604914616 cites W1994453326 @default.
- W2604914616 cites W2006908560 @default.
- W2604914616 cites W2009559825 @default.
- W2604914616 cites W2013458750 @default.
- W2604914616 cites W2022319000 @default.
- W2604914616 cites W2022993650 @default.
- W2604914616 cites W2026572108 @default.
- W2604914616 cites W2032144646 @default.
- W2604914616 cites W2033718483 @default.
- W2604914616 cites W2034248832 @default.
- W2604914616 cites W2034416546 @default.
- W2604914616 cites W2079810030 @default.
- W2604914616 cites W2090816940 @default.
- W2604914616 cites W2121829592 @default.
- W2604914616 cites W2160502426 @default.
- W2604914616 cites W2247640319 @default.
- W2604914616 cites W2282617321 @default.
- W2604914616 cites W2286011408 @default.
- W2604914616 cites W2312475473 @default.
- W2604914616 cites W2344893465 @default.
- W2604914616 cites W4247835256 @default.
- W2604914616 cites W44333684 @default.
- W2604914616 doi "https://doi.org/10.2106/jbjs.16.00296" @default.
- W2604914616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28375887" @default.
- W2604914616 hasPublicationYear "2017" @default.
- W2604914616 type Work @default.
- W2604914616 sameAs 2604914616 @default.
- W2604914616 citedByCount "76" @default.
- W2604914616 countsByYear W26049146162017 @default.
- W2604914616 countsByYear W26049146162018 @default.
- W2604914616 countsByYear W26049146162019 @default.
- W2604914616 countsByYear W26049146162020 @default.
- W2604914616 countsByYear W26049146162021 @default.
- W2604914616 countsByYear W26049146162022 @default.
- W2604914616 countsByYear W26049146162023 @default.
- W2604914616 crossrefType "journal-article" @default.
- W2604914616 hasAuthorship W2604914616A5006226053 @default.
- W2604914616 hasAuthorship W2604914616A5007247253 @default.
- W2604914616 hasAuthorship W2604914616A5033038090 @default.
- W2604914616 hasAuthorship W2604914616A5045525636 @default.
- W2604914616 hasAuthorship W2604914616A5075639504 @default.
- W2604914616 hasAuthorship W2604914616A5085565942 @default.
- W2604914616 hasConcept C126322002 @default.
- W2604914616 hasConcept C141071460 @default.
- W2604914616 hasConcept C14184104 @default.
- W2604914616 hasConcept C168563851 @default.
- W2604914616 hasConcept C170493617 @default.
- W2604914616 hasConcept C2775849661 @default.
- W2604914616 hasConcept C2777389121 @default.
- W2604914616 hasConcept C2777876916 @default.
- W2604914616 hasConcept C2778336525 @default.
- W2604914616 hasConcept C2778468042 @default.
- W2604914616 hasConcept C2781151446 @default.
- W2604914616 hasConcept C2781328992 @default.
- W2604914616 hasConcept C42219234 @default.
- W2604914616 hasConcept C71924100 @default.
- W2604914616 hasConceptScore W2604914616C126322002 @default.
- W2604914616 hasConceptScore W2604914616C141071460 @default.
- W2604914616 hasConceptScore W2604914616C14184104 @default.
- W2604914616 hasConceptScore W2604914616C168563851 @default.
- W2604914616 hasConceptScore W2604914616C170493617 @default.
- W2604914616 hasConceptScore W2604914616C2775849661 @default.
- W2604914616 hasConceptScore W2604914616C2777389121 @default.
- W2604914616 hasConceptScore W2604914616C2777876916 @default.
- W2604914616 hasConceptScore W2604914616C2778336525 @default.
- W2604914616 hasConceptScore W2604914616C2778468042 @default.
- W2604914616 hasConceptScore W2604914616C2781151446 @default.
- W2604914616 hasConceptScore W2604914616C2781328992 @default.
- W2604914616 hasConceptScore W2604914616C42219234 @default.
- W2604914616 hasConceptScore W2604914616C71924100 @default.
- W2604914616 hasIssue "7" @default.
- W2604914616 hasLocation W26049146161 @default.
- W2604914616 hasLocation W26049146162 @default.
- W2604914616 hasOpenAccess W2604914616 @default.
- W2604914616 hasPrimaryLocation W26049146161 @default.
- W2604914616 hasRelatedWork W2013575488 @default.
- W2604914616 hasRelatedWork W2096587559 @default.
- W2604914616 hasRelatedWork W2346129146 @default.
- W2604914616 hasRelatedWork W2368707258 @default.
- W2604914616 hasRelatedWork W2549085913 @default.